Childhood Atropine For Myopia Progression

Abstract

Myopia progression is safely and effectively reduced by topical administration of a storage-stable low-dose formulation in which atropine is present at a concentration of 0.01%. Unexpectedly, such formulation was proven more effective to reduce myopia progression as compared to an otherwise identical formulation containing 0.02% atropine. For example, formulations with an atropine concentration of about 0.01% slowed down myopia progression as compared to subjects not receiving treatment.

CPC Classifications